Aspirin resistance and atherothrombosis;Resistência à aspirina e aterotrombose

Brazilian Journal of Cardiovascular Surgery

Volumn 22, Issue 1, 2007, Pages 96-103

  Gabriel, Sthefano Atique ^c   Beteli, Camila Baumann ^d   Taniguchi, Rodrigo Seiji ^d   Tristão, Cristiane Knopp ^d   Gabriel, Edmo Atique ^a   Job, José Roberto Pretel Pereira ^b  

^a FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^b Medicine Department

^c Bairro Jardim Vergueiro   (Brazil)

^d NONE

Author keywords

Aspirin; Cardiovascular diseases, prevention control; Drug resistance; Thrombosis, prevention control

Indexed keywords

EID: 34447135573     PISSN: 01027638     EISSN: 16789741     Source Type: Journal    
DOI: 10.1590/S0102-76382007000100017     Document Type: Review

References (37)

1. Mason PJ, Jacobs AK, Freedman JE. Aspirin resistance and atherothrombotic disease. J Am Coll Cardiol. 2005;46(6):986-93.
2. Mckee SA, Sane DC, Deliargyris EN. Aspirin resistance in cardiovascular disease: a review of prevalence, mechanisms, and clinical significance. Thromb Haemost. 2002;88(5):711-5.
3. Ribeiro RA, Mello RG, Melchior R, Dill JC, Hohmann CB, Lucchese AM, et al. Custo anual do manejo da cardiopatia isquêmica crônica no Brasil: perspectiva pública e privada. Arq Bras Cardiol. 2005;85(1):3-8.
4. Antiplatelet Trialists' Collaboration. Collaborative overview of randomised trials of antiplatelet therapy. I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ. 1994;308(6921):81-106.
5. Steering Committee of the Physicians' Health Study Research Group. Final report on the aspirin component of the ongoing Physicians' Health study. N Engl J Med. 1989;321(3):129-35.
6. Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BJM. 2002;324:71-86.
7. Buchanan MR, Brister SJ. Individual variation in the effects of ASA on platelet function: implications for the use of ASA clinically. Can J Cardiol. 1995;11(3):221-7.
8. Chen WH, Lee PY, Ng W, Tse HF, Lau CP. Aspirin resistance is associated with a high incidence of myonecrosis after non-urgent percutaneous coronary intervention despite clopidogrel pretreatment. J Am Coll Cardiol. 2004;43(6):1122-6.
9. Gum PA, Kottke-Marchant K, Welsh PA, White J, Topol EJ. A prospective, blinded determination of the natural history of aspirin resistance among stable patients with cardiovascular disease. J Am Coll Cardiol. 2003;41(6):961-5.
10. McNicol A, Israels SJ. Platelets and anti-platelet therapy. J Pharmacol Sci. 2003;93(4):381-96.
11. Patrono C, Bachmann F, Baigent C, Bode C, De Caterina R, Charbonnier B, et al. Expert consensus document on the use of antiplatelet agents. The Task Force on the Use of Antiplatelet Agents in Patients with Atherosclerotic Cardiovascular Disease of the European Society of Cardiology. Eur Heart J. 2004;25(2):166-81.
12. Patrono C, Coller B, FitzGerald GA, Hirsh J, Roth G. Platelet-active drugs: the relationships among dose, effectiveness, and side effects: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest. 2004;126(3 suppl):234S-64S.
13. Patrono C, Coller B, Dalen JE, FitzGerald GA, Fuster V, Gent M, et al. Platelet-active drugs: the relationships among dose, effectiveness, and side effects. Chest. 2001;119(1 suppl.):39S-63S.
14. Awtry EH, Loscalzo J. Aspirin. Circulation. 2000;101(10):1206-18.
15. Damas JK, Waehre T, Yndestad A, Otterdal K, Hognestad A, Solum NO, et al. Interleukin-7-mediated inflammation in unstable angina: possible role of chemokines and platelets. Circulation. 2003;107(21):2670-6.
16. Patrono C. Aspirin as an antiplatelet drug. N Engl J Med. 1994;330(18):1287-94.
17. Patrono C. Aspirin resistance: definition, mechanisms and clinical read-outs. J Thromb Haemost. 2003;1(18):1710-3.
18. Hankey GJ, Eikelboom JW. Aspirin resistance. Lancet. 2006;367(9510):606- 17.
19. Mehta J, Mehta P, Burger C, Pepine CJ. Platelet aggregation studies in coronary artery disease. Atherosclerosis. 1978;31(2):169-75.
20. Gabriel SA, Tristão CK, Izar LC, Domingues C, Gabriel EA, Cliquet MG. Avaliação da agregação plaquetária e dosagem do fibrinogênio em pacientes com doenças cardiovasculares e sua correlação com o uso de aspirina e fatores de risco coronariano. Rev Bras Cir Cardiovasc. 2006;21(3):289-94.
21. Pappas JM, Westengard JC, Bull BS. Population variability in the effect of aspirin on platelet function. Implications for clinical trials and therapy. Arch Pathol Lab Med. 1994;118(8):801-4.
22. Grotemeyer KH, Scharafinski HW, Husstedt IW. Two-year follow-up of aspirin responder and aspirin non-responders. A pilot-study including 180 post-stroke patients. Thromb Res. 1993;71(5):397-403.
23. Grundmann K, Jaschonek K, Kleine B, Dichgans J, Topka H. Aspirin non-responder status in patients with recurrent cerebral ischemic attacks. J Neurol. 2003;250(1):63-6.
24. Mueller MR, Salat A, Stangl P, Murabito M, Pulaki S, Boehm D, et al. Variable platelet response to low-dose ASA and the risk of limb deterioration in patients submitted to peripheral arterial angioplasty. Thromb Haemost. 1997;78(3):1003-7.
25. Alexander JH, Harrington RA, Tuttle RH, Berdan LG, Lincoff AM, Deckers, JW, et al. Prior aspirin use predicts worse outcomes in patients with non-ST-elevation acute coronary syndromes. PURSUIT Investigators. Platelet IIb/IIIa in Unstable angina: Receptor Suppression Using Integrilin Therapy. Am J Cardiol. 1999;83(8):1147-51.
26. III Diretrizes Brasileiras sobre Dislipidemias e Diretriz de Prevenção da Aterosclerose do Departamento de Aterosclerose da Sociedade Brasileira de Cardiologia. Arq Bras Cardiol. 2001;77(supl 3):1-48.
27. Lima RC, Kubrusly LF, Nery AC, Pinheiro BB, Brick AV, Souza DSR, et al. Diretrizes da cirurgia de revascularização miocárdica, valvopatias e doenças da aorta. Arq Bras Cardiol. 2004;82(suppl 5):1-20.
28. César LAM, Mansur AP, Armaganijan D, Amino JG, Sousa AC, Simão AF, et al. Diretrizes de doença coronariana crônica angina estável. Arq Bras Cardiol. 2004;83(suppl 2): 2-43.
29. Brockmann MA, Beythien C, Magens MM, Wilckens V, Kuehnl P, Gutensohn K. Platelet hemostasis capacity in smokers. In vitro function analyses with 3.2% citrated whole blood. Thromb Res. 2001;104(5):333-42.
30. Cotter G, Shemesh E, Zehavi M, Dinur I, Rudnick A, Milo O, et al. Lack of aspirin effect: aspirin resistance or resistance to taking aspirin? Am Heart J. 2004;147(2):293-300.
31. Kurth T, Glynn RJ, Walker AM, Chan KA, Buring JE, Hennekens CH, et al. Inhibition of clinical benefits of aspirin on first myocardial infarction by nonsteroidal antiinflammatory drugs. Circulation. 2003;108(10):1191-5.
32. Pulcinelli FM, Pignatelli P, Celestini A, Riondino S, Gazzaniga PP, Violi F. Inhibition of platelet aggregation by aspirin progressively decreases in long-term treated patients. J Am Coll Cardiol. 2004;43(6):979-84.
33. Hurlen M, Seljeflot I, Arnesen H. Increased platelet aggregability during exercise in patients with previous myocardial infarction. Lack of inhibition by aspirin. Thromb Res. 2000;99(5):487-94.
34. Kawasaki T, Ozeki Y, Igawa T, Kambayahsi J. Increased platelet sensitivity to collagen in individuals resistant to low-dose aspirin. Stroke. 2000;31(3):591-5.
35. Cipollone F, Rocca B, Patrono C. Ciclooxygenase-2 expression and inhibition in atherothrombosis. Arterioscler Thromb Vasc Biol. 2004;24(2):246-55.
36. Freedman JE. CD40-CD40L and platelet function: beyond hemostasis. Cir Res. 2003;92(9):944-6.
37. Sabatine MS, Cannon CP, Gibson CM, Lopez-Sendon JL, Montalescot G, Theroux P, et al. Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation. N Engl J Med. 2005;352(25):1179-89.